Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03372902 · ClinicalTrials.gov registry record
Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 628
- Enrollment target
NCT03372902: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03372902 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 628 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03372902 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 628 participants
- Enrollment target
Study Summary
The purpose of this study is to collect blood and tissue to help develop tests that might be able to detect cancer earlier. The investigator will be collecting these samples and reviewing test results from participants who have had an area of concern found on breast imaging, as well as from participants who are scheduled to have a routine breast cancer screening mammogram.
Primary Outcome
result of the biopsy of the BIRADS 4 breast
Interventions
- OTHER Blood draw
- DEVICE Breast MRI
- DEVICE Breast Mammogram
- PROCEDURE Breast Biopsy
- BEHAVIORAL online participant reported questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 628 participants |
| Start Date | 2017-12-07 |
| Est. Completion | 2025-03-12 |
What the finished NCT03372902 record still lists
NCT03372902 is an observational study that tracks outcomes without assigning an intervention. The registered 628 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which Blood draw is the first listed.
NCT03372902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03372902 about?
NCT03372902 is a clinical study titled "Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening". The purpose of this study is to collect blood and tissue to help develop tests that might be able to detect cancer earlier. The investigator will be collecting these samples and reviewing test results from participants who have had an area of concern found on breast imaging, as well as from particip...
What is the current status of trial NCT03372902?
This trial is currently completed. The enrollment target is 628 participants. The study started on 2017-12-07. Estimated completion is 2025-03-12.
What interventions are being tested in trial NCT03372902?
The interventions under investigation include: Blood draw (OTHER), Breast MRI (DEVICE), Breast Mammogram (DEVICE), Breast Biopsy (PROCEDURE), online participant reported questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT03372902?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI